Komori
Tms (4891) · InitiativeAdvanced

Issuance of Stock Options as Equity Compensation

First written in FY2024-Q1. 5 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: FY2027-H1.

7entries
4years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024-Q1AdvancedFY2025-H1AdvancedFY2026-H1 – FY2027-H12023: 120232024: 120242025: 220252026: 32026
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 656 companies write about · 0 as a headwind · 737 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 739 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1AdvancedAnnual report

    「Resolution date 15 April 2026 Class and number of grantees 5 Company directors 4 Company statutory auditors 14 Company employees Number of warrants* 4,248 Class, description and number of underlying shares* 424,800 common shares」

    The 12th Series Warrants, totaling 4,248 warrants representing 424,800 common shares, were issued to 5 directors, 4 statutory auditors and 14 employees. The equity-compensation program provides staged vesting over 1, 2 and 3 years.
  2. FY2026-H1AdvancedAnnual report

    「Warrants issued during the interim accounting period were as follows: resolution date, 13 June 2025; class and number of grantees, 2 Company directors and employees; number of warrants, 548; class and number of underlying shares, 54,800 common shares.」

    The 11th Series Warrants resolved on 13 June 2025 were issued to 2 directors and employees, comprising 548 warrants representing 54,800 common shares.
  3. FY2025RestatedAnnual report

    「Directors’ compensation comprises basic compensation as fixed compensation, directors’ bonuses as monetary compensation other than basic compensation, and stock-option compensation as non-monetary compensation.」

    The Company continues its stock-option program for directors, statutory auditors and employees, with compensation determined through the compensation committee framework.
  4. FY2025-H1AdvancedAnnual report

    「Warrants issued during the interim accounting period were as follows: resolution date, 18 July 2024; class and number of grantees, 5 Company employees; number of warrants, 458; class and number of underlying shares, 45,800 common shares.」

    The 9th Series Warrants resolved on 18 July 2024 were issued to 5 employees, comprising 458 warrants representing 45,800 common shares.
  5. FY2024-Q1First statedAnnual report

    「At a meeting of the Board of Directors held on 15 June 2023, the Company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue warrants as stock options to its directors, including outside directors, statutory auditors and employees, and issued them on 10 July 2023.」

    The Company issued equity-compensation stock options to directors, statutory auditors and employees to align them with share-price gains and risks and encourage improved performance, corporate value and social trust. The 1,681 warrants represented 100 common shares each, were allotted on 10 July 2023 and vest in stages over 1, 2 and 3 years.
Moved together

"Preclinical development and preparation for Phase I clinical trials of TMS-008" moved the same way as this thread, in the same document, in 3 of its 7 moves.

332222★123456
  1. ★This thread
  2. 1Preclinical development and preparation for Phase I clinical trials of TMS-0083×
  3. 2Acquisition of an exclusive worldwide license for TMS-010 (a drug candidate for spinal cord injury treatment)3×
  4. 3Funding Through the Tenth Series of Stock Acquisition Rights2×
  5. 4Out-licensing of TMS-007 and Late-Stage Phase II Clinical Trial2×
  6. 5Managing the Development Process and Strengthening the Pipeline Toward Launch2×
  7. 6Introduction of Academia-Based Drug Discovery Seeds and Bridging to Global Markets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tms yet. It last moved in the Share Issuance and Disposal of 2026-05-12: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Issuance of Stock Options as Equity Compensation | TMS Co.,Ltd. (4891) | Komori